Background: To examine the association between metformin use and mortality in patients with
Introduction
Metformin, an inexpensive, first-line oral drug treatment for type 2 diabetes, is thought to inhibit cancer growth by lowering circulating insulin level or directly activating the AMPactivated protein kinase (AMPK) pathway (1) . Work from our group also discovered that metformin can enhance tumor response to radiation by inhibiting tumor cell oxygen consumption (i.e. improving tumor oxygenation) (2) . Poor tumor oxygenation (hypoxia) has been independently associated with inferior survival in cervix cancer, and with increased metastasis and resistance to chemotherapy and radiotherapy (3, 4) . Metformin has been found to be associated with a significant reduction in cancer-specific mortality in patients with diabetes (HR, 0.74; 95% CI, 0.62-0.88) on meta-analysis of observational studies, though limited to colon cancer on subgroup analyses (5) . However, no study to date has investigated the association between metformin and cervical cancer-specific mortality. We therefore examined whether cumulative metformin exposure is associated with lower mortality among women with diabetes diagnosed with cervical cancer.
Materials and Methods
The institutional review board approved this population-based, retrospective cohort study, with waiver of informed consent.
Data Sources
All Ontario residents are covered under a universal health plan; those age ≥ 65 are also covered for prescription drugs. We used the following population-based health care databases, which are linkable through a unique, anonymized identifier: the Ontario Drug Benefit database (6) , which contains all dispensed prescriptions for those age ≥ 65; the Ontario Cancer Registry (OCR), a population-based cancer registry that is more than 95.0% complete (7) ; the Ontario Diabetes Database (8) , a validated administrative data-derived registry of patients with diabetes; the Canadian Institute of Health Information (CIHI) Discharge Abstract Database (DAD) (9) , which contains diagnostic and procedure information on all hospital admissions; the National Ambulatory Care Reporting System (NACRS), which captures information on emergency department visits; and the Ontario Health Insurance Plan (OHIP) claims database (10) 
Cohort Definition
We used the OCR to identify women age ≥ 66 diagnosed with incident cervical cancer (as their first cancer) in Ontario between July 1, 1997 and December 31, 2010 (n = 1415). The cohort was restricted to women age ≥ 66 to capture medication data and have a 1-year look-back, and limited to those diagnosed with diabetes on the same day as or prior to cervical cancer (n = 342) using the Ontario Diabetes Database. Finally, those who did not receive definitive treatment (surgery or radiotherapy consisting of external beam radiotherapy and brachytherapy) for their cervical cancer (n = 110), and those diagnosed with another (non-cervical) cancer were excluded (n = 51).
Outcomes
The primary outcome was cervical cancer-specific mortality, based on the validated cause-of-death variable from the OCR (11, 12) . The secondary outcome was overall mortality, based on death records from RPDB.
Medication Exposure
All prescriptions for anti-diabetic medications were identified from the Ontario Drug Benefit database starting from the date of cancer diagnosis. These medications were categorized into metformin, other oral anti-diabetics (e.g. sulfonylureas, thiazolidinediones, meglitinides, gliptins, acarbose) and insulin. Given that previous studies (13, 14) and ours did not observe an association between metformin exposure prior to cancer diagnosis and cancer outcome, we focused on medication exposure after cervical cancer diagnosis. Exposure to anti-diabetic medications was defined in two ways. For primary analysis, the cumulative dose of metformin after cervical cancer diagnosis was calculated by multiplying the dose and quantity of tablets dispensed per prescription and summing the cumulative dose of each metformin prescription until the last follow-up date. For secondary analysis, the cumulative duration of metformin use was calculated by summing the durations of each metformin prescription between the date of cervical cancer diagnosis and last follow-up. Cumulative dose of metformin was the preferred method of measuring exposure because the dose of metformin taken per day varied widely; however, it was not possible to sum up the cumulative dose of other anti-diabetic medications (e.g. 1mg of glyburide not equivalent to 1mg of pioglitazone). A time-varying approach was used, whereby a subject's exposure classification was allowed to vary over time, depending on the prescriptions filled. If a medication was discontinued, the cumulative dose or duration of exposure remained the same as the value at the time the previous prescription expired. 
Other Covariates
In addition to medication exposure, other factors potentially associated with overall and cervical cancer-specific mortality were evaluated: age; comorbidity based on the Johns Hopkins Adjusted Clinical Groups Case-Mix System weighted adjusted diagnostic groups (ADG) score (which has been shown to predict mortality in a population-based Ontario sample of patients with diabetes (15)); socioeconomic status; duration of diabetes at cervical cancer diagnosis; year of cervical cancer diagnosis (to adjust for temporal changes in management of cervical cancer and diabetes); histology (squamous cell carcinoma vs others); and treatment (surgery, radical radiation, or radical chemoradiation). Primary treatment was identified using billing, intervention and/or procedure codes for surgery, radiation and chemotherapy from OHIP, CIHI DAD and NACRS databases. Treatment information was also available from Cancer Care Ontario for cases diagnosed from 2006 onward.
Statistical Analysis
To avoid guarantee-time bias (16) , medication exposures after cervical cancer diagnosis were modeled as time-varying covariates. The association between cumulative dose or duration of exposure to anti-diabetic medication and cervical cancer-specific mortality was assessed using a Fine and Gray competing-risk regression model (17) , with death from other causes as competing risk. This approach takes into account the fact that women who died of other causes (competing events) will never die of cervical cancer, and hence provides more realistic estimates.
The association with overall mortality was assessed by a Cox proportional hazard model. assumption of proportional (subdistribution) hazards was examined using Schoenfeld residuals.
Model results were reported using adjusted hazard ratios (HRs) with 95% confidence intervals.
All P values were 2-sided with a significance level of < 0.05. R version 3.1.0 was used for all analyses.
Sensitivity Analyses
To explore the robustness of our results, we restricted the cohort to those treated with definitive radiation ± concurrent chemotherapy (i.e. excluded those treated with definitive surgery) and repeated the analyses. We could not perform sensitivity analysis on those treated with surgery because of the limited number of events (8) in that group.
Results
During the study period, 181 women with diabetes ≥ age 66 were diagnosed with and received definitive treatment for cervical cancer in Ontario (Table 1) . Median follow-up time of all women was 3.9 years (interquartile range [IQR], 1.5-7.2 years), and 5.8 years (IQR 4.2-9.6 years) for those still alive. During the follow-up period, 110 women (60.8%) were prescribed metformin, 129 died (71.3%) and 61 (33.7%) died of cervical cancer. Metformin users were exposed to metformin for a median of 25.9 months (IQR 9.5-57.0 months) after cervical cancer diagnosis. There were no significant differences in baseline patient or tumor characteristics between metformin users and nonusers (Table 1) , except for a trend towards younger age in metformin users (Fisher's exact test p = 0.07).
Cervical-Cancer Specific Mortality
Year of cervical cancer diagnosis, histology and treatment formed the baseline multivariable clinical model for cervical-cancer specific mortality (Table 2) 
year of metformin use and cervical cancer-specific mortality was 0.77 (95% CI 0.55-1.1, P = 0.15), and 0.86 (95% CI 0.76-0.98, P = 0.02) for overall mortality.
Discussion
This population-based study suggests that cumulative dose of metformin use after cervical cancer diagnosis among older women with diabetes is associated with significant decrease in cervical cancer-specific and overall mortality. For every additional 365g of metformin (i.e. equivalent to taking 1g of metformin daily x 365 days), there is a 21.4% decrease of cervical cancer-specific mortality. This is the first study to our knowledge to investigate a potential benefit of metformin therapy for cervical cancer.
There are many potential biologic mechanisms underlying the effects of metformin in cervical cancer. Metformin has been shown to inhibit cervical cancer growth in vitro via various pathways, such as the Wnt/β-catenin/DVL3 and LKB1/AMPK/mTOR signaling pathways (18) (19) (20) . Radiotherapy is the primary modality of treatment for locally advanced cervical cancer, and metformin has been shown to radio-sensitize lung cancer cells in vivo (21) . Finally, our group has shown that metformin can decrease tumor hypoxia and improve tumor response to radiotherapy in vivo. When we restricted the analysis to those treated with definitive radiotherapy, cumulative dose of metformin remained associated with significant decrease in cervical cancer-specific and overall mortality. Given that a significant proportion of locally advanced cervical cancer are hypoxic, we are conducting a phase II trial randomizing women to the anti-cancer effect of phenformin (a metformin analogue) (22) ; 38-60% of cervical cancer harbor mitochondrial DNA mutation (23, 24) .
Several studies have evaluated the effect of metformin therapy on other cancers among patients with diabetes; many did not account for non-cancer death as a competing risk. We performed competing risk analysis for the cervical cancer-specific mortality endpoint, because the risk of death due to causes other than cancer is high in older women with diabetes. Indeed, there were slightly more non-cervical cancer deaths than cervical cancer deaths in this cohort.
Interestingly, when we analyzed the cervical cancer-specific mortality endpoint using Cox regression (i.e. ignoring non-cervical cancer death as a competing risk), both the HR and P values became smaller: HR 0.72 per each additional 365g of metformin use after cervical cancer diagnosis, 95% CI 0.57-0.90, P = 0.004; and HR 0.69 per each additional year of metformin use, 95% CI 0.5-0.95, P = 0.02. There remained no significant association between other anti-diabetic medication exposure and cervical cancer-specific mortality. In a previous population-based study on prostate cancer, metformin was also the only anti-diabetic drug associated with decreased cancer-specific and overall mortality, when considering all drug exposures as time-varying covariates on Cox regression analysis (13) .
We modeled medication exposures after cervical cancer diagnosis as time-varying covariates to avoid guarantee-time bias (16) , and also as cumulative exposure to evaluate doseresponse effect. Guarantee-time bias has been a concern in prior studies that dichotomized metformin exposure as a never/ever fixed variable based on baseline exposure or exposure that occurred during the follow-up period (25) . Patients who die early in the follow-up period have less opportunity to be exposed to metformin; those who live longer have more opportunity to be exposed to metformin. Using the fixed approached, patients who did not use metformin at the time of cohort entry but started using it later during the follow-up period would be misclassified as "exposed" to metformin during the time between cohort entry and the first metformin prescription (25) . Thus, the potential benefits of metformin are exaggerated with a fixed (timeindependent) approach. Our time-varying medication exposures were modeled as cumulative exposures after cervical cancer diagnosis, allowing for comparison not just between users and nonusers, but also between users who had different doses of cumulative exposure. We observed a dose-dependent effect. While this finding does not prove causality, it strengthens the evidence.
The cumulative approach should also help mitigate the healthy-user effect and other indication biases (13, 26) . The cumulative duration of metformin use was not significantly associated with cervical cancer-specific mortality (but exhibited an effect in the same direction as cumulative dose of metformin) likely due to the variation in daily metformin dose across patients (e.g. 0.5g, 1g, 1.5g, 2g or 2.5g per day).
As with other population-based retrospective studies, our study has some limitations.
First, it is an observational study where metformin use was not randomly assigned. While we tried to minimize potential biases, we cannot correct for all sources of bias, especially those that cannot be measured. As we did not use a cohort of women with incident diabetes, the possibility of selection bias based on differing diabetes severity exists. However, we found no significant association between the duration of diabetes at the time of cervical cancer diagnosis (surrogate for severity of diabetes) and cervical cancer-specific mortality. In summary, our study is the first to report that cumulative metformin use after cervical cancer diagnosis may be associated with decreased cervical cancer-specific and overall mortality among older women with diabetes. The potential of metformin to improve cervical cancer outcome deserves further interventional studies in depth. 76 (42) 38 (21) 67 (37) 53 (48) 23 (21) 34 (31) 23 (32) 15 (21) 33 ( 31 (17) 42 (23) 25 (14) 18 (10) 1 34 (31) 19 (17) 27 (25) 20 (18) 9 (8) 1 30 (42) 12 (17) 15 (21) 5 (7) 9 (13) 94 (52) 46 (25) 110 (100) 76 (69) 29 (26) 0 (0) 18 (25) 17 ( 
